PennPET Explorer Scanner Evaluation

  • STATUS
    Recruiting
  • End date
    May 3, 2025
  • participants needed
    99
  • sponsor
    University of Pennsylvania
Updated on 3 February 2021

Summary

Positron Emission Tomography (PET) is a procedure that uses a special type of machine to take pictures of the inside of the body after a radioactive drug is administered. The radioactive drug that is used for this study may be an FDA approved imaging drug or may be used as an investigational imaging drug as part of another study for which participants are taking part. PET using various radiotracers is useful for the diagnosis of various diseases, including cancer, brain diseases, infection, and heart or lung disease.

The purpose of this study is to test a research PET machine called the PennPET Explorer long-axial field-of-view scanner. This research PET machine can image a larger section of the body than the current clinical PET scanners, allowing most of the body to be imaged at one time. This scanner is still an investigational device and is being tested in this study to collect more information about how best to use this type of whole body scanner.

Description

The PennPET Explorer is a multiring system with a long AFOV that is scalable and comprised of multiple 22.9 cm long ring segments, each with 18 detector modules based on a commercial digital silicon photomultiplier. Initial testing data on a prototype 3-ring-segment instrument with an active 64-cm AFOV has been collected and published by Karp et al., and Pantel et al., [Karp 2020, Pantel 2020], validating the system design and demonstrating its initial performance.

In the last two decades, commercial PET scanner performance has improved dramatically with CT-based attenuation correction 1, the use of lutetium oxyorthosilicate or lutetium-yttrium oxyorthosilicate scintillators, time-of-flight reconstruction 2-5, and, most recently, silicon photomultiplier (SiPM)-based time-of-flight detectors 2,6. However, the AFOV has not grown; it remains 16-26 cm for the newest commercial SiPM-based scanners 7,8. This choice is due mainly to scintillator and SiPM photosensor costs and the prevalence of clinical 18F-FDG scanning focused on measuring lesion SUV when the uptake is assumed to be at steady state, typically at 60 min after injection. The newest commercial instruments perform an 18F-FDG whole-body survey (skull-base to mid-thigh) with excellent diagnostic quality in 10-20 min using bed translation.

The motivation for a LAFOV PET system is to use its high sensitivity to enhance clinical performance and to enable research applications. Clinically, a LAFOV system could enable faster imaging, imaging with lower injected activities, or a combination of the two. Research applications include delayed imaging, improving quantification for kinetic modeling, and applications requiring simultaneous measurement of multiple organ systems 9,10. It is unknown whether such a system would primarily be used for clinical or research applications. The investigators developed the PennPET Explorer whole-body imager to support both applications. Performance measurements were taken on the prototype 3-ring-segment system to optimize the hardware and software acquisition and reconstruction, as well as to demonstrate the capabilities of the PennPET Explorer. The investigators are currently increasing the number or ring-segments to a total of 6 which will give an active 140 cm AFOV. This will allow whole-body imaging in one bed position for most adults.

In the evaluation of a new instrument, human studies are essential to establish the real-world performance beyond phantom studies, as well as to test and optimize data acquisition and reconstruction. To date 10 human studies have been imaged on the prototype scanner under IRB 809476. This instrument was determined by the FDA to meet the definition of a nonsignificant risk (NSR) device and is therefore subject only to abbreviated IDE requirements. Once the additional ring-segments have been added to the instrument, the investigators plan to continue testing this scanner in human subjects under this ongoing open-ended protocol. The investigators will continue to work towards optimizing performance and data acquisition until such time as this device receives full FDA 510(k) approval.

This protocol is designed to test the PennPET Explorer instrument with its final AFOV of 140 cm. PET imaging involves the administration of a radioactive imaging drug that emits positrons which are detected by the scanner and used to form the images. For the purposes of this protocol, the administered radioactive imaging drug (tracer) will vary; it may be an FDA-approved radiotracer or an experimental radiotracer that is used under an IND. If the radiotracer used is under an IND, then the administration of the radiotracer will be done under the purview of a separate protocol for which the subject has been separately consented. This protocol and the corresponding ICF involves consent only for being scanned on the investigational scanner and does not pertain to the administration of an investigational radiopharmaceutical.

Details
Condition healthy
Treatment Long AFOV PennPET Explorer
Clinical Study IdentifierNCT04617912
SponsorUniversity of Pennsylvania
Last Modified on3 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Adult participants, at least 18 years of age
Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures

Exclusion Criteria

Inability to tolerate imaging procedure in the opinion of an investigator
Serious or unstable medical or psychological conditions or lack of mobility that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note